Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer

por Bloem, Lourens T., De Abreu Lourenço, Richard, Chin, Melvin, Ly, Brett, Haas, Marion
Publicado 2016

Genome-wide copy number variations as molecular diagnostic tool for cutaneous intermediate melanocytic lesions: a systematic review and individual patient data meta-analysis

por Ebbelaar, Chiel F., Jansen, Anne M. L., Bloem, Lourens T., Blokx, Willeke A. M.
Publicado 2021

Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs

por Vreman, Rick A., Bouvy, Jacoline C., Bloem, Lourens T., Hövels, Anke M., Mantel‐Teeuwisse, Aukje K., Leufkens, Hubert G.M., Goettsch, Wim G.
Publicado 2018

Pre‐approval and post‐approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs

por Bloem, Lourens T., Bot, Rosa E., Mantel‐Teeuwisse, Aukje K., van der Elst, Menno E., Sonke, Gabe S., Klungel, Olaf H., Leufkens, Hubert G. M., Hoekman, Jarno
Publicado 2022

The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs

por Vreman, Rick A., Bloem, Lourens T., van Oirschot, Stijn, Hoekman, Jarno, van der Elst, Menno E., Leufkens, Hubert GM, Klungel, Olaf H., Goettsch, Wim G., Mantel-Teeuwisse, Aukje K.
Publicado 2020

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies

por Bloem, Lourens T., Vreman, Rick A., Peeters, Niels W. L., Hoekman, Jarno, van der Elst, Menno E., Leufkens, Hubert G. M., Klungel, Olaf H., Goettsch, Wim G., Mantel‐Teeuwisse, Aukje K.
Publicado 2021